Goldman Sachs Initiates Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $135

Futu NewsDec 21 02:31 · Ratings

Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135

BenzingaDec 20 20:51 · Ratings

Vaxcyte Analyst Ratings

BenzingaDec 20 20:49 · Ratings

Vaxcyte Insider Sold Shares Worth $710,249, According to a Recent SEC Filing

MT NewswiresDec 20 05:11

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Simply Wall StDec 8 21:49

Vaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock Potential

TipRanksDec 6 13:56